A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide is a research paper published in The Oncologist (2022). On theSindex it has a DataRank of 0.790. It has been cited 24 times, with 24 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0.307
From 19 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 24 citers.
National Institutes of Health
Grant: ZIA BC 010547
Intramural NIH HHS
Grant: Z01 BC010547
National Institutes of Health
Grant: 1Z01BC010547-04
Development of Drugs That Target Prostate Cancer
National Cancer Institute
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals